IN8bio (INAB) Q3 2026 earnings summary

Executive summary

• Cash of $14.0M at September 30, 2026 is expected to fund operations through April 2027; continued development and planned milestones depend on securing additional capital.

• Appointed Oxana Polyakova, Ph.D., as SVP of R&D in September; she brings 20 years of experience in gamma-delta T-cell biology and biologics development.

Financial highlights

• Q3 operating expenses were $4.721M vs. $3.967M YoY; R&D was $2.599M vs. $2.104M and G&A was $2.122M vs. $1.863M.

• Q3 net loss was $4.592M vs. $3.854M; nine-month net loss was $14.463M vs. $14.498M, on operating expenses of $14.922M vs. $14.828M.

• Nine-month R&D was $7.705M vs. $7.563M; higher TCE preclinical and personnel costs were largely offset by lower INB-400 clinical and facility costs.

• Nine-month G&A was $7.217M vs. $7.265M, primarily reflecting lower personnel-related costs, including stock-based compensation, and reduced professional services.

Outlook and guidance

• Initial in vivo data for INB-619 are expected by year-end 2026; timing and planned milestones are contingent on a successful additional capital raise.

• INB-100 expansion-cohort treatment is expected to finish with a clinical update at ASH in December 2026; further INB-400 overall-survival follow-up is expected at SNO in November 2026.

• Forward-looking milestones include preclinical and clinical data readouts, patient dosing timelines, and FDA guidance on regulatory pathways for the DeltEx DRI GBM program.